Drug Trial Radar · NCT05307705
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
May 11, 2022
Primary completion
Apr 2, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Conditions
- Breast Cancer
Interventions
LOXO-783Drug
Oral
FulvestrantDrug
Intramuscular
ImlunestrantDrug
Oral
AbemaciclibDrug
Oral
Anastrozole, Exemestane, or LetrozoleDrug
Oral
PaclitaxelDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)Time frame: During the first 28-day cycle of LOXO-783 treatment
- Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicitiesTime frame: During the first 28-day cycle of LOXO-783 treatment
Locations
50 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic of Scottsdale
Scottsdale, Arizona
UCLA Medical Center
Los Angeles, California
UCSF Medical Center at Mission Bay
San Francisco, California
Stanford University Hospital
Stanford, California
Mayo Clinic
Jacksonville, Florida
Winship Cancer Center Emory University
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Washington University Medical School
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Wilmot Cancer Institute
Rochester, New York
Tennessee Oncology PLLC
Nashville, Tennessee
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
Cancer Research SA
Adelaide, Australia
Peter Maccallum Cancer Institute Erb
East Melbourne, Australia
St Vincent's Hospital
Sydney, Australia
Institut Jules Bordet
Anderlecht, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Princess Margaret Hospital (Hong Kong)
Toronto, Canada
BC Cancer Vancouver
Vancouver, Canada
Beijing Cancer hospital
Beijing, China
The Third Hospital of Nanchang
Nanchang, China
Fudan University Shanghai Cancer Center
Shanghai, China
Centre Leon Berard
Lyon, France
Institut Curie
Paris, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
ICANS_Institut de Cancerologie Strasbourg Europe
Strasbourg, France
Gustave Roussy
Villejuif, France
Universitätsklinikum Erlangen
Erlangen, Germany
National Cancer Center Hospital
Chūōku, Japan
The Cancer Institute Hospital of JFCR
Kōtō City, Japan
Kyoto University Hospital
Kyoto, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
National Cancer Centre Singapore
Singapore, Singapore
Samsung Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.